Market Place
Sourcing Support
All News #Library
Biotech
Alto Halts Work On PDE4 Inhibitor After Ph. 2 Schizophrenia Fail
02 Apr 2026 //
FIERCE BIOTECH
Alto Neuroscience Wraps Up Enrollment of ALTO-101 Phase 2 Study
13 Feb 2026 //
BUSINESSWIRE
Alto Neuroscience Secures Patent for ALTO-207 in Depression
14 Jan 2026 //
BUSINESSWIRE
Alto Neuro to Advance ALTO-207 for Treatment-Resistant Depression
20 Oct 2025 //
BUSINESSWIRE
Alto Neuroscience Reveals $50M Private Placement Financing
20 Oct 2025 //
BUSINESSWIRE
Alto Neuro`s ALTO-101 Granted FDA Fast Track Designation
03 Oct 2025 //
BUSINESSWIRE
Alto’s Phase 2 Depression Trial Misses Primary Efficacy Endpoint
27 Jun 2025 //
FIERCE BIOTECH
Alto’s midphase depression trial falls flat
23 Oct 2024 //
FIERCE BIOTECH
Alto Neuroscience to Participate in Upcoming Investor Conferences
03 Sep 2024 //
BUSINESSWIRE
Mid-stage CNS biotech Alto Neuroscience files for NYSE listing
15 Jan 2024 //
ENDPTS
Alto Neuro CEO, Amit Etkin to Participate in National Academies of Sciences
07 Mar 2023 //
BUSINESSWIRE
Copyright © 2026 LePro PharmaCompass OPC Private Limited, All rights reserved.